Medshine Discovery Inc.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Guangdong Raynovent Biotech Co., Ltd.

Other

Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.

Cspc Zhongqi Pharmaceutical Technology (shijiazhuang) Co., Ltd.

Shandong Danhong Pharmaceutical Co., Ltd.

Qilu Pharmaceutical Co., Ltd.

Sichuan University

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Yangtze River Pharmaceutical Group Co., Ltd.

Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

Shandong Luye Pharmaceutical Co., Ltd.

Jiangsu Kanion Pharmaceutical Co., Ltd.

Nanjing Sanhome Pharmaceutical Co., Ltd.

Shuhui Chen

Jian Li

Charles Z Ding

Guoping Hu

Haiying He

Lihong Hu

Lingyun Wu

Chengde Wu

Wenyuan Qian

Jie Li

Peng Li

Kevin X Chen

Zhengxia Chen

Xiaoxin Chen

Chaofeng Long

Tao Yu

Wentao Wu

Chundao Yang

Changqing Wei

Hao Wu

Fang Liu

Yunfu Luo

Zhigan Jiang

Zhuowei Liu

Zhen Gong

Cheng Xie

Peng Zhang

Yong Wang

Fei Sun

Zhi Luo

Jian Xiong

Xiaolin Li

Bin Chen

Zhaozhong Ding

Fei Wang

Qinghua Mao

Yuan Chen

Xiquan Zhang

Zheng Wang

Kai Zhou

Xuanjia Peng

Weidong Li

Chen Zhang

Xing Liu

Lei Zhang

Wei Luo

Cheng Li

Ling Yang

Tie-Lin Wang

Yuquan Wei

Yong Xu

Lie Li

Shilan Liu

Ning Li

Weihua Shi

Wei Huang

Wei Wang

Xiao Xun Zhang

Jing Wang

Hui Liu

Jun Yin

Hongwei Li

Cong Wang

Hongjiang Xu

Feng Gao

Tao Feng

Jing Zhang

Zhiqiang Liu

Dahai Wang

Jun Lin

Bo Gao

Ting Wang

Yan Wang

Jian Wang

Yong Liang Liu

Ming Zhang

Yi Bu Li

Bin Liu

Yi Chen

Yang Zhang

Jiong Lan

Chun Sing Li

Lu Zhang

Feng Guo

Wei Wei

Wei Gu

Kun Peng Wang

Jun Yu

Rui Zhao

Xin Tian

Ling Liu

Xu Zeng

Hui Zhou

Aiming Zhang

Jun Zhao

Liang Shen

Disclosed in the present invention is a series of dimethylsulfoximine derivatives, and specifically disclosed are a compound represented by formula (II) and a pharmaceutically acceptable salt thereof.

Dimethylsulfoximine derivative

Compounds as SGLT2/DPP4 dual inhibitors, and application in preparation of medicines as the SGLT2/DPP4 dual inhibitors. A compound represented by formula (I), and an isomer or pharmaceutically acceptable salt thereof are specifically involved.

SGLT2/DPP4 inhibitor and application thereof

A class of KRAS G12C mutant protein inhibitors, specifically disclosing the compound shown in formula (I), and an isomer and a pharmaceutically acceptable salt thereof.

Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor

A novel indazole compound, a preparation method therefor, and use thereof in the preparation of drugs for treating related diseases. Specifically disclosed are a compound of formula (II) and a pharmaceutically acceptable salt thereof.

Indazole-fused cyclic compound

Disclosed are a series of benzopyrimidine compounds and a use thereof, and specifically disclosed are compounds represented by formula (II) and pharmaceutically acceptable salts thereof.

Benzopyrimidine compounds and use thereof

A class of salt forms and crystal forms of a tetrahydrocyclohepta indazole compound and a preparation method therefor. Specifically disclosed is the uses of the salt form and crystal form of the compound of formula (I) in the preparation of a drug for treating related diseases.

Salt form and crystal form of tetrahydrocyclohepta indazole compound

Disclosed are the solid form, crystalline form, crystal form A of a compound of formula (I), and a preparation method therefor, crystal form B and a preparation method therefor. Also disclosed are use of the solid form, crystalline form, crystal form A, and crystal form B in the preparation of drugs for the treatment of diseases related to FGFR.

FGFR inhibitor compound in solid form and preparation method therefor

A Spiro compound serving as an ERK inhibitor, and an application thereof in preparing a drug for treating an ERK-related disease. The present invention specifically relates to a compound represented by formula (III) or a pharmaceutically acceptable salt thereof.

Spiro compound serving as ERK inhibitor, and application thereof

FGFR and VEGFR dual inhibitors, specifically being a compound represented by formula (I) or a pharmaceutically acceptable salt.

Pyridine derivative as FGFR and VEGFR dual inhibitors

Disclosed are a pyrrolopyrimidine compound and a use thereof in preparing a medicine for diseases related to a BTK protein kinase inhibitor. Specially, disclosed are a compound as shown in formula (III) and a pharmaceutically acceptable salt thereof.

Pyrrolopyrimidine compound as BTK inhibitor and use thereof

A class of compounds as a SGLT1/SGLT2/DPP4 triple inhibitor, and an application in preparation of a drug serving as the SGLT1/SGLT2/DPP4 triple inhibitor. Compounds represented by formula (I), and isomers and pharmaceutically-acceptable salts thereof are specifically involved.

SGLTS/DPP4 inhibitor and application thereof

Disclosed is a class of porcupine inhibitors, specifically a compound as represented by formula (I), and a pharmaceutically acceptable salt or an isomer thereof.

Compound as porcupine inhibitor and use thereof

Provided are a crystal of a compound of formula (I), salt thereof, a crystal of the salt thereof, and a preparation method for the crystal. Also comprised are applications of the compound and the crystal in preparation of drugs for treating IRAK4-related diseases.

IRAK4 inhibitor crystal and preparation method therefor

A compound represented by formula (I), isomers or pharmaceutically acceptable salts thereof, and application thereof in the preparation of drugs for treating diseases related to RIP-1 (receptor interacting protein) kinase.

Bicyclic compound as RIP-1 kinase inhibitor and application thereof

The present invention relates to a pyrrolopyrimidine compound used as a JAK inhibitor, and the use thereof in the preparation of a drug for treating a JAK1- and/or JAK2-associated disease, and in specifically relates to a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.

Pyrrolopyrimidine compound and use thereof

Growing community of inventors

Shanghai, China

Shuhui Chen